Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Shares Outstanding (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Shares Outstanding for 6 consecutive years, with $3.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding fell 77.07% to $3.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.2 million, a 77.07% decrease, with the full-year FY2024 number at $1.4 million, down 56.91% from a year prior.
  • Shares Outstanding was $3.2 million for Q3 2025 at Ensysce Biosciences, up from $2.4 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $24.3 million in Q2 2021 to a low of $35650.0 in Q4 2022.
  • A 5-year average of $3.3 million and a median of $1.3 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: crashed 99.24% in 2022, then skyrocketed 1703.46% in 2023.
  • Ensysce Biosciences' Shares Outstanding stood at $102678.0 in 2021, then crashed by 65.28% to $35650.0 in 2022, then surged by 488.33% to $209739.0 in 2023, then surged by 546.41% to $1.4 million in 2024, then skyrocketed by 134.63% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Shares Outstanding are $3.2 million (Q3 2025), $2.4 million (Q2 2025), and $1.6 million (Q1 2025).